{"result": "(\"entity\"<|>GSDVI<|>EVENT<|>GSDVI is a rare metabolic disorder caused by a mutation in the liver isoform of glycogen phosphorylase, leading to issues with glycogenolysis and presenting symptoms such as hepatomegaly and hypoglycemia in early childhood.)\n##\n(\"entity\"<|>GSDIX<|>EVENT<|>GSDIX is the most common glycogen storage disease, caused by mutations in genes coding for phosphorylase b kinase, leading to symptoms like hepatomegaly and hypoglycemia, particularly during fasting.)\n##\n(\"entity\"<|>PYGL<|>ORGANIZATION<|>PYGL is the gene responsible for encoding the liver isoform of glycogen phosphorylase, which is crucial for glycogenolysis.)\n##\n(\"entity\"<|>VITAMIN B6<|>ORGANIZATION<|>Vitamin B6 is a nutrient that has been studied for its potential benefits in managing glycogen storage diseases, although results have been inconclusive.)\n##\n(\"entity\"<|>CREATINE<|>ORGANIZATION<|>Creatine is a supplement that has been tested in clinical trials for its effects on exercise tolerance in patients with glycogen storage diseases, with mixed results.)\n##\n(\"entity\"<|>ALMIDÓN DE MAÍZ<|>ORGANIZATION<|>Corn starch is a dietary supplement recommended for patients with glycogen storage diseases to help manage symptoms and improve energy levels.)\n##\n(\"relationship\"<|>GSDVI<|>PYGL<|>GSDVI is caused by a mutation in the PYGL gene, which affects glycogen metabolism<|>9)\n##\n(\"relationship\"<|>GSDIX<|>PYGL<|>GSDIX is related to the function of the PYGL gene, as it involves the regulation of glycogen metabolism<|>7)\n##\n(\"relationship\"<|>GSDVI<|>CREATINE<|>Creatine has been studied for its effects on exercise tolerance in patients with GSDVI<|>5)\n##\n(\"relationship\"<|>GSDIX<|>CREATINE<|>Creatine has been tested in clinical trials for its effects on exercise tolerance in patients with GSDIX<|>5)\n##\n(\"relationship\"<|>GSDVI<|>ALMIDÓN DE MAÍZ<|>Corn starch is recommended for patients with GSDVI to help manage their symptoms<|>8)\n##\n(\"relationship\"<|>GSDIX<|>ALMIDÓN DE MAÍZ<|>Corn starch is recommended for patients with GSDIX to help manage their symptoms<|>8)\n##\n(\"relationship\"<|>GSDVI<|>VITAMIN B6<|>Vitamin B6 has been studied for its potential benefits in managing symptoms of GSDVI<|>4)\n##\n(\"relationship\"<|>GSDIX<|>VITAMIN B6<|>Vitamin B6 has been studied for its potential benefits in managing symptoms of GSDIX<|>4)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: toma de azúcares                            mediante amniocentesis o biopsia corial.\nantes de iniciar el ejercicio puede disminuir la moviliza-\nción de lípidos que se produce de forma normal cuan-                           1.6.2.    Objetivos nutricionales y\ndo éste se realiza de forma prolongada, y de hecho con                                   recomendaciones dietéticas\nla suplementación de HC de absorción rápida el fenó-\nmeno     second wind        se minimiza o no se produce en                       Habitualmente los pacientes no precisan tratamiento\nmuchos casos. A pesar de ello, como se ha comentado,                           para mantener los niveles de glucemia, ya que la enfer-\nla tolerancia al ejercicio es mayor.                                           medad tiene un curso benigno. En caso de presentar\n   También se han realizado estudios con suplementos                           hipoglucemias, más frecuente en los primeros años, se\nde creatina con resultados contradictorios. En un ensayo                       realizará una dieta rica en HC y ligeramente hiperpro-\nse observó mejoría de la capacidad ante ejercicio isomé-                       teica (15-25% del valor calórico total) con ingestas fre-\ntrico isquémico pero no frente a ejercicio no isquémico                        cuentes y suplementación con almidón crudo de maíz\ncon dosis bajas (60 mg/kg/d). En otro ensayo clínico con                       (1,5-2 g/kg administrados de una a tres veces al día)\nsuplementos de creatina a dosis altas (150 mg/kg/d) em-                        (Ver GSDI). No obstante, parece que el aumento del\npeoró la tolerancia al ejercicio, por lo que parece que el                     aporte de los HC tiene beneficios más allá. Se ha obser-\nefecto pudiera ser dosis-dependiente. Se han intentado                         vado que en los niños mejora el crecimiento, aumenta\notras estrategias como la suplementación con vitamina                          la densidad mineral ósea y disminuye la hepatomega-\nB6 o aminoácidos ramificados sin resultados satisfacto-                        lia. Por otra parte, los niños mayores y adultos, aunque\nrios que justifiquen su uso.                                                   no tengan hipoglucemias, presentan una mejoría de la\n                                                                               energía y calidad de vida con una dosis de almidón de\n1.6.    Déficit de fosforilasa hepática, glucogenosis                          maíz (1,5-2 g/kg) antes de dormir. La monitorización\n        tipo VI o enfermedad de Hers (GSDVI)                                   de la glucemia y cetonemia capilar puede ayudar a\n                                                                               ajustar el aporte de HC a las necesidades de cada indi-\n1.6.1.     Fisiopatología y diagnóstico                                        viduo y evitar el sobretratamiento.\n   La GSDVI se produce por la mutación de la isoforma                          1.7.   Déficit de fosforilasa-b-kinasa o\nhepática      de    la  glucógeno       fosforilasa     (gen    PYGL,                 glucogenosis tipo IX\n14q22.1), enzima limitante de la glucogenólisis, que\ncataliza la escisión de los enlaces α-1,4 del glucógeno                        1.7.1.    Fisiopatología y diagnóstico\nliberando Glu-1-P. A diferencia de la GSDI la gluconeo-\ngénesis es eficaz, por lo que los niveles de glucemia se                         La GSDIX es la glucogenosis más frecuente (25% de\nmantienen gracias a esta ruta metabólica.                                      todas   las   GSD),    con    una    prevalencia     estimada     de\n   Se trata de una enfermedad rara, y de curso benigno                         1:100.000, aunque puede ser mayor, ya que muchos\nque se manifiesta a edad temprana, generalmente duran-                         casos pueden no estar diagnosticados dada su clínica\nte la lactancia o infancia. La clínica consiste en hepatome-                   leve. Está producida por la mutación de alguno de los\ngalia con elevación leve de transaminasas, hipoglucemia                        genes que codifican la fosforilasa-b-kinasa, enzima\nleve tras ayuno en caso de enfermedad, hipoglucemia                            que por un lado activa la glucógeno fosforilasa permi-\ncetósica tras ayuno durante toda la noche, hiperlipemia                        tiendo el inicio de la glucogenólisis, y por otro inactiva\nleve y retraso del crecimiento. A largo plazo puede apare-                     la glucógeno sintasa inhibiendo así la glucogenogéne-\ncer osteoporosis en pacientes no tratados. Los síntomas                        sis. Esta proteína está constituida por cuatro subunida-\nmejoran con la edad y en la mayoría de los casos la hepa-                      des, cada una de ellas codificada por un gen diferente:\ntomegalia desaparece y los individuos alcanzan su talla                        α (con dos\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}